View : 131 Download: 19
Predicting amyloid PET positivity using plasma p-tau181 and other blood-based biomarkers
- Title
- Predicting amyloid PET positivity using plasma p-tau181 and other blood-based biomarkers
- Authors
- Kwon; Hyuk Sung; Lee; Eun-Hye; Kim; Hyung-Ji; Park; Jee Hyang; Koh; Seong-Ho; Choi; Seong Hye; Jae-Hong; So-Hee; Hyun-Hee; Jeong
- Ewha Authors
- 정지향
- SCOPUS Author ID
- 정지향
- Issue Date
- 2023
- Journal Title
- Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
- ISSN
- 2352-8729
- Citation
- Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring vol. 15, no. 4
- Keywords
- Alzheimer's disease; amyloid beta; amyloid positron emission tomography; APOE; neurofilament light; p-tau181
- Publisher
- John Wiley and Sons Inc
- Indexed
- SCOPUS
- Document Type
- Article
- Abstract
- Introduction: This study aimed to determine the efficacy of combining plasma phosphorylated tau (p-tau)181, amyloid beta (Aβ)42/Aβ40, neurofilament light (NfL), and apolipoprotein E (APOE) genotypes for detecting positive amyloid positron emission tomography (PET), which is little known in the Asian population, in two independent cohorts. Methods: Biomarkers were measured using a single-molecule array (Simoa) in a cohort study (Asan). All participants underwent amyloid PET. Significant changes in the area under the curve (AUC) and Akaike Information Criterion values were considered to determine the best model. The generalizability of this model was tested using another cohort (KBASE-V). Results: In the Asan cohort, after adjusting for age and sex, p-tau181 (AUC = 0.854) or APOE ε4 status (AUC = 0.769) distinguished Aβ status with high accuracy. Combining them or adding NfL and Aβ42/40 improved model fitness. The best-fit model included the plasma p-tau181, APOE ε4, NfL and Aβ42/40. The models established from the Asan cohort were tested in the KBASE-V cohort. Additionally, in the KBASE-V cohort, these three biomarker models had similar AUC in cognitively unimpaired (AUC = 0.768) and mild cognitive impairment (MCI) (AUC = 0.997) participants. Conclusions: Plasma p-tau181 showed a high performance in determining Aβ-PET positivity. Adding plasma NfL and APOE ε4 status improved the model fit without significant improvement in AUC. © 2023 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.
- DOI
- 10.1002/dad2.12502
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
-
Alz Dem Diag Ass Dis Mo - 2023 - Kwon - Predicting amyloid PET positivity using plasma p‐tau181 and other blood‐based.pdf(924.2 kB)
Download
- Export
- RIS (EndNote)
- XLS (Excel)
- XML